Literature DB >> 27053844

Serrated colorectal cancer: Molecular classification, prognosis, and response to chemotherapy.

Oscar Murcia1, Miriam Juárez1, Eva Hernández-Illán1, Cecilia Egoavil1, Mar Giner-Calabuig1, María Rodríguez-Soler1, Rodrigo Jover1.   

Abstract

Molecular advances support the existence of an alternative pathway of colorectal carcinogenesis that is based on the hypermethylation of specific DNA regions that silences tumor suppressor genes. This alternative pathway has been called the serrated pathway due to the serrated appearance of tumors in histological analysis. New classifications for colorectal cancer (CRC) were proposed recently based on genetic profiles that show four types of molecular alterations: BRAF gene mutations, KRAS gene mutations, microsatellite instability, and hypermethylation of CpG islands. This review summarizes what is known about the serrated pathway of CRC, including CRC molecular and clinical features, prognosis, and response to chemotherapy.

Entities:  

Keywords:  CIMP; Chemotherapy; Colorectal cancer; Methylator phenotype; Serrated pathway

Mesh:

Substances:

Year:  2016        PMID: 27053844      PMCID: PMC4814638          DOI: 10.3748/wjg.v22.i13.3516

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  120 in total

1.  Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803.

Authors:  Shuji Ogino; Kaori Shima; Jeffrey A Meyerhardt; Nadine J McCleary; Kimmie Ng; Donna Hollis; Leonard B Saltz; Robert J Mayer; Paul Schaefer; Renaud Whittom; Alexander Hantel; Al B Benson; Donna Spiegelman; Richard M Goldberg; Monica M Bertagnolli; Charles S Fuchs
Journal:  Clin Cancer Res       Date:  2011-12-06       Impact factor: 12.531

2.  Molecular features of colorectal hyperplastic polyps and sessile serrated adenoma/polyps from Korea.

Authors:  Kyoung-Mee Kim; Eui Jin Lee; Sangyun Ha; So Young Kang; Kee-Taek Jang; Cheol Keun Park; Jin Yong Kim; Young Ho Kim; Dong Kyung Chang; Robert Daniel Odze
Journal:  Am J Surg Pathol       Date:  2011-09       Impact factor: 6.394

3.  EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib.

Authors:  Ryan B Corcoran; Hiromichi Ebi; Alexa B Turke; Erin M Coffee; Michiya Nishino; Alexandria P Cogdill; Ronald D Brown; Patricia Della Pelle; Dora Dias-Santagata; Kenneth E Hung; Keith T Flaherty; Adriano Piris; Jennifer A Wargo; Jeffrey Settleman; Mari Mino-Kenudson; Jeffrey A Engelman
Journal:  Cancer Discov       Date:  2012-01-16       Impact factor: 39.397

4.  CpG island methylator phenotype (CIMP) of colorectal cancer is best characterised by quantitative DNA methylation analysis and prospective cohort studies.

Authors:  S Ogino; M Cantor; T Kawasaki; M Brahmandam; G J Kirkner; D J Weisenberger; M Campan; P W Laird; M Loda; C S Fuchs
Journal:  Gut       Date:  2006-01-11       Impact factor: 23.059

5.  BRAF mutations in colorectal cancer are associated with distinct clinical characteristics and worse prognosis.

Authors:  Matthew F Kalady; Kathryn L Dejulius; Julian A Sanchez; Awad Jarrar; Xiuli Liu; Elena Manilich; Marek Skacel; James M Church
Journal:  Dis Colon Rectum       Date:  2012-02       Impact factor: 4.585

6.  Comparison of microsatellite instability, CpG island methylation phenotype, BRAF and KRAS status in serrated polyps and traditional adenomas indicates separate pathways to distinct colorectal carcinoma end points.

Authors:  Michael J O'Brien; Shi Yang; Charline Mack; Huihong Xu; Christopher S Huang; Elizabeth Mulcahy; Mark Amorosino; Francis A Farraye
Journal:  Am J Surg Pathol       Date:  2006-12       Impact factor: 6.394

7.  BRAF and KRAS Mutations in hyperplastic polyps and serrated adenomas of the colorectum: relationship to histology and CpG island methylation status.

Authors:  Shi Yang; Francis A Farraye; Charline Mack; Oksana Posnik; Michael J O'Brien
Journal:  Am J Surg Pathol       Date:  2004-11       Impact factor: 6.394

8.  KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803.

Authors:  Shuji Ogino; Jeffrey A Meyerhardt; Natsumi Irahara; Donna Niedzwiecki; Donna Hollis; Leonard B Saltz; Robert J Mayer; Paul Schaefer; Renaud Whittom; Alexander Hantel; Al B Benson; Richard M Goldberg; Monica M Bertagnolli; Charles S Fuchs
Journal:  Clin Cancer Res       Date:  2009-11-24       Impact factor: 12.531

9.  Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.

Authors:  Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray
Journal:  Int J Cancer       Date:  2014-10-09       Impact factor: 7.396

10.  DNA methylation of the p14ARF, RASSF1A and APC1A genes as an independent prognostic factor in colorectal cancer patients.

Authors:  Torbjörn K Nilsson; Zarah M Löf-Öhlin; Xiao-Feng Sun
Journal:  Int J Oncol       Date:  2012-10-30       Impact factor: 5.650

View more
  11 in total

1.  A bispecific nanobody approach to leverage the potent and widely applicable tumor cytolytic capacity of Vγ9Vδ2-T cells.

Authors:  Renée C G de Bruin; John P Veluchamy; Sinéad M Lougheed; Famke L Schneiders; Silvia Lopez-Lastra; Roeland Lameris; Anita G Stam; Zsolt Sebestyen; Jürgen Kuball; Carla F M Molthoff; Erik Hooijberg; Rob C Roovers; James P Di Santo; Paul M P van Bergen En Henegouwen; Henk M W Verheul; Tanja D de Gruijl; Hans J van der Vliet
Journal:  Oncoimmunology       Date:  2017-10-20       Impact factor: 8.110

2.  Molecular Pathogenesis and Classification of Colorectal Carcinoma.

Authors:  Anup Kasi; Shivani Handa; Sajjad Bhatti; Shahid Umar; Ajay Bansal; Weijing Sun
Journal:  Curr Colorectal Cancer Rep       Date:  2020-08-15

3.  Dual specificity phosphatase 5 is a novel prognostic indicator for patients with advanced colorectal cancer.

Authors:  Xuebing Yan; Liguo Liu; Hao Li; Linsheng Huang; Mingming Yin; Cheng Pan; Huanlong Qin; Zhiming Jin
Journal:  Am J Cancer Res       Date:  2016-10-01       Impact factor: 6.166

4.  Molecular Oncology in Management of Colorectal Cancer.

Authors:  Ramraj Nagendra Gupta Vemala; Sanjeev Vasudev Katti; Bhawna Sirohi; Divya Manikandan; Govind Nandakumar
Journal:  Indian J Surg Oncol       Date:  2021-03-16

5.  Separation of low and high grade colon and rectum carcinoma by eukaryotic translation initiation factors 1, 5 and 6.

Authors:  Nicole Golob-Schwarzl; Caroline Schweiger; Carina Koller; Stefanie Krassnig; Margit Gogg-Kamerer; Nadine Gantenbein; Anna M Toeglhofer; Christina Wodlej; Helmut Bergler; Brigitte Pertschy; Stefan Uranitsch; Magdalena Holter; Amin El-Heliebi; Julia Fuchs; Andreas Punschart; Philipp Stiegler; Marlen Keil; Jens Hoffmann; David Henderson; Hans Lehrach; Christoph Reinhard; Christian Regenbrecht; Rudolf Schicho; Peter Fickert; Sigurd Lax; Johannes Haybaeck
Journal:  Oncotarget       Date:  2017-09-05

6.  Deep Learning With Sampling in Colon Cancer Histology.

Authors:  Mary Shapcott; Katherine J Hewitt; Nasir Rajpoot
Journal:  Front Bioeng Biotechnol       Date:  2019-03-27

7.  Cimp-Positive Status is More Representative in Multiple Colorectal Cancers than in Unique Primary Colorectal Cancers.

Authors:  Sandra Tapial; Susana Olmedillas-López; Daniel Rueda; María Arriba; Juan L García; Alfredo Vivas; Jessica Pérez; Laura Pena-Couso; Rocío Olivera; Yolanda Rodríguez; Mariano García-Arranz; Damián García-Olmo; Rogelio González-Sarmiento; Miguel Urioste; Ajay Goel; José Perea
Journal:  Sci Rep       Date:  2019-07-19       Impact factor: 4.379

8.  Automated imaging cytometry reveals dysplastic indices of colonic serrated adenomas.

Authors:  Nicholas S Samel; Qin Huang; Hiroshi Mashimo
Journal:  Future Sci OA       Date:  2020-02-21

Review 9.  Organoid models of gastrointestinal cancers in basic and translational research.

Authors:  Harry Cheuk Hay Lau; Onno Kranenburg; Haipeng Xiao; Jun Yu
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-02-25       Impact factor: 46.802

10.  Prevalence of the BRAF p.v600e variant in patients with colorectal cancer from Mexico and its estimated frequency in Latin American and Caribbean populations.

Authors:  Jesús Arturo Hernández-Sandoval; Melva Gutiérrez-Angulo; María Teresa Magaña-Torres; Carlos Rogelio Alvizo-Rodríguez; Helen Haydee Fernanda Ramírez-Plascencia; Beatriz Armida Flores-López; Jesús Alonso Valenzuela-Pérez; Jorge Peregrina-Sandoval; José Miguel Moreno-Ortiz; Mev Domínguez-Valentín; María de la Luz Ayala-Madrigal
Journal:  J Investig Med       Date:  2020-03-16       Impact factor: 2.895

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.